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Abstract
Background: Real-time PCR (qPCR) based methods, such as the Xpert MTB/RIF, are increasingly being used to diagnose
tuberculosis (TB). While qualitative methods are adequate for diagnosis, the therapeutic monitoring of TB patients
requires quantitative methods currently performed using smear microscopy. The potential use of quantitative molecular
measurements for therapeutic monitoring has been investigated but findings have been variable and inconclusive.
The lack of an adequate reference method and reference materials is a barrier to understanding the source of such
disagreement. Digital PCR (dPCR) offers the potential for an accurate method for quantification of specific DNA sequences
in reference materials which can be used to evaluate quantitative molecular methods for TB treatment monitoring.
Methods: To assess a novel approach for the development of quality assurance materials we used dPCR to quantify
specific DNA sequences in a range of prototype reference materials and evaluated accuracy between different
laboratories and instruments. The materials were then also used to evaluate the quantitative performance of qPCR and
Xpert MTB/RIF in eight clinical testing laboratories.
Results: dPCR was found to provide results in good agreement with the other methods tested and to be highly
reproducible between laboratories without calibration even when using different instruments. When the reference
materials were analysed with qPCR and Xpert MTB/RIF by clinical laboratories, all laboratories were able to correctly rank
the reference materials according to concentration, however there was a marked difference in the measured magnitude.
Conclusions: TB is a disease where the quantification of the pathogen could lead to better patient management and
qPCR methods offer the potential to rapidly perform such analysis. However, our findings suggest that when precisely
characterised materials are used to evaluate qPCR methods, the measurement result variation is too high to determine
whether molecular quantification of Mycobacterium tuberculosis would provide a clinically useful readout. The methods
described in this study provide a means by which the technical performance of quantitative molecular methods can be
evaluated independently of clinical variability to improve accuracy of measurement results. These will assist in ultimately
increasing the likelihood that such approaches could be used to improve patient management of TB.
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Background
Using molecular methods, such as the polymerase chain
reaction (PCR), to diagnose tuberculosis (TB) offers the
potential for a simple, rapid and objective alternative to
microbial culture and smear microscopy. While there
have been a range of commercially available tuberculosis
molecular diagnostic tests for over 15 years [1] it is the
introduction of the Cepheid Xpert® MTB/RIF test (Xpert
MTB/RIF) [2], and its subsequent recommendation by
the WHO [3], that has changed how molecular based
methods are viewed as tools that could impact on the
management of this global disease. As a consequence,
the Xpert MTB/RIF has been rolled out in a number of
countries in the developing world [4] and is the most
commonly used direct molecular test in countries like
the United Kingdom [5].
As molecular diagnosis of TB becomes more wide-
spread there is the need to support the routine applica-
tion of such methods through the development and
application of reference materials for the calibration of
in vitro diagnostics and external quality assessment
(EQA), both of which are scarce. There is often a regula-
tory requirement to use EQA so it is vital that proper
quality controlled methods are developed. The proper
calibration of such in vitro diagnostics is in many places,
such as the European Union where the Directive on in
vitro diagnostic medical devices 98/79/EC applies, a re-
quirement. A limited portfolio of nucleic acid and bac-
terial extract materials has been developed as quality
assurance controls for molecular diagnosis of tubercu-
losis [6, 7]. These have been prepared and characterised
using a variety of methods including colony forming
units (CFU) counting and real-time quantitative PCR
(qPCR), to support methods like the Xpert MTB/RIF.
These reference standards are important developments
as they enable laboratories to compare the performance
of various TB diagnostic tests performed in house, while
also facilitating comparisons of the associated diagnostic
services offered nationally and eventually between coun-
tries. However, to have the greatest impact, these mate-
rials should be evaluated with an independent method
with a high level of accuracy to enable a judgement
about the equivalence of measurement results obtained
with materials from different EQA providers, or even
batches from the same scheme. Such reference methods
are common in clinical biochemical measurement [8],
however to date do not exist for molecular microbio-
logical measurement.
While TB is diagnosed using a qualitative approach,
with clinical decisions made on presence or absence of the
pathogen, it also represents an example where pathogen
quantification is desirable as a potential indicator to
determine treatment efficacy and predict relapse.
Quantification is currently applied in patient management
by grading of smear positivity and there are a number of
studies that have used more sophisticated culture based
quantitative metrics such as CFU counting and time to
positivity [9, 10] as well a molecular based methods target-
ing RNA [11, 12] and DNA using PCR [13, 14] and, in-
creasingly, qPCR using the Xpert MTB/RIF [15–18].
Where the quantitative capabilities of the Xpert MTB/RIF
have been evaluated its value as a quantitative method is
equivocal. In some studies it correlated with other
methods in pulmonary TB [15, 17, 19] whereas in others
it was found not to agree with culture methods reported
as being superior [16].
To resolve such disagreement, and ultimately determine
the efficacy of quantitative molecular measurement using
any method, a metrological approach can be adopted and
analytical and biological sources of variation defined.
Defining the former measurement uncertainty [20] allows
improvements to be made on the analysis method, while
the latter provides information on what is clinically pos-
sible. To accurately determine the error and define the
quantitative performance of a given method across differ-
ent laboratories, rigorously characterised materials are re-
quired of which property values have been determined
using a high accuracy method [21]. Digital PCR (dPCR)
[22, 23] may offer such an approach through binary count-
ing of the number of pathogen genomes present which
does not rely on an additional calibration material like
qPCR, and has been successfully used in the quantification
of a range of microorganisms [24–29]. dPCR is more pre-
cise than qPCR [30] and offers a potentially accurate
method for quantifying pathogens in reference materials
when coupled with an efficient extraction protocol [24]. In
dPCR a limiting dilution of the template is initially per-
formed into many small volume partitions prior to running
the PCR reactions. Following the reaction quantification is
achieved by measuring partitions as either negative
(without template) or positive (with template). In this study
we investigated the accuracy (comprising sources of bias
and precision) of dPCR for quantifying sequence-specific
DNA concentration in EQA materials that were then used
to characterise the qualitative and quantitative perform-
ance of molecular diagnostic testing across eight different
clinical laboratories applying qPCR and Xpert MTB/RIF.
Methods
Three different experimental comparisions were per-
formed in the study to assess the performance of dPCR
when measuring M. tuberculosis in terms of 1) quantifi-
cation, 2) reproducibility and 3) performance in support-
ing molecular quantification using routine clinical tests.
Study materials
To enable the characterisation of dPCR reproducibility
and to determine sources of error, three different types
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of reference materials were investigated comprising gene
fragments cloned into a plasmid, genomic DNA (gDNA)
and whole mycobacteria in synthetic sputum [31].
To assess dPCR quantification reproducibility when
measuring the gene targets without the presence of a
large more complex genome, a ‘TB Control plasmid’ was
used [24]. This consisted of a pUC19 plasmid containing
an insert including 16S rRNA and rpoB genes from M.
tuberculosis. The linearised plasmid (Additional file 1:
Method 1) was gravimetrically diluted to ~105 copies/μL,
in a DNA carrier of sonicated human gDNA (Cambio)
diluted to 25 ng/μL in 1× TE pH 8.0 (Ambion), as
described in the Additional file 2. Two hundred × 50 μL
units of the diluted plasmid were added into low DNA
binding microcentrifuge tubes and stored at −20 °C.
To assess dPCR quantification reproducibility when meas-
uring targets using gDNA, a material comprising a commer-
cial preparation of gDNA from M. tuberculosis (Zopf)
Lehmann and Neumann (ATCC® 25618™), was prepared
(H37Rv gDNA). The gDNA was initially quantified by fluo-
rimetry using a dsDNA BR assay (Qubit, Thermo Fisher Sci-
entific), and was subsequently gravimetrically diluted to
approximately 105 copies/μL in 1× TE pH 8.0 (Ambion) con-
taining ~25 ng/μL sonicated human genomic DNA. Two
hundred units consisting of ~50 μL diluted gDNA were pro-
duced in low DNA binding tubes and stored at −20 °C.
To assess reproducibility of dPCR measurements,
when including the extraction step necessary for clinical
analysis, two additional materials were used:
A) 300 units of a whole mycobacterial panel in artificial
sputum (BCG/ASM) were prepared. Mycobacterium
bovis BCG strain Pasteur (BCG) was grown in 7H9
liquid medium (Becton-Dickinson (BD)) containing
10 % albumin-dextrose-catalase (ADC) (BD) enrich-
ment medium
and 0.2 % Tween 80. CFU (mean 1.09 × 108 ± SD
1.98 × 107 per mL) was determined using the Miles and
Misra method [32] and nine serial dilutions of the
stock culture were plated onto 7H10 solid agar (BD)
containing 10 % OADC (oleic acid-albumin-dextrose-
catalase, BD) and 0.5 % glyercol. Artificial sputum
matrix (ASM) was prepared according to Dinesh [31].
Each unit of BCG/ASM material was prepared
containing 100 μL BCG suspension and 900 μL ASM.
Aliquots were centrifuged 18,000 × g for 10 min and
bacterial pellets were resuspended in 400 μL 1 ×TE
buffer followed by heat treatment for 30 min at 95 °C
and frozen at −80 °C.
B) For the clinical laboratory comparison an additional
whole mycobacterial material preparation was used.
‘Total MTB Control’ was supplied by Vircell
(Santa Fe, Spain) as AMPLIRUN® Total MTB
Control (Sputum); product reference MTBC013.
DNA extraction
For assessment of dPCR when measuring whole myco-
bacteria, DNA was extracted from BCG/ASM and Total
MTB Control materials using the Cetyltrimethylammo-
nium bromide (CTAB) NaCl method [33] as described
in Addititonal file 1 with a final resuspension volume of
200 μL. For gDNA extraction from the Total MTB
Control, the lyophilised material was initially reconsti-
tuted in 400 μL nuclease free water (Ambion) and the
final pellet was resuspended in 50 μL TE buffer (Fluka).
For the comparision of qPCR by the clinical labora-
toraties three specified extraction protocols were
followed (details in Additional file 1: Table S4).
dPCR method
Primers/hydrolysis probes (Additional file 1: Table S1)
used for quantification of 16S rRNA and rpoB genome
copies were as described [12, 24]. dPCR was performed on
the Biomark HD System for Genetic Analysis (Fluidigm,
San Francisco, CA) using 48-panel 37 K dPCR integrated
fluidic circuits, the QuantStudio® 3D Digital PCR System
using QuantStudio® 3D Digital PCR Chips (ThermoFisher
Scienific) or the QX100 Droplet Digital PCR System
(Bio-Rad) with respective reaction mixes as per Additional
file 2 and thermal cycling parameters as per Additional
file 1: Table S2. The concentrations, termed λ (also known
copies per partition), of the different templates added to
the different dPCR reactions are described in Additional
file 1: Table S3. The dMIQE (Minimum Information for
publication of Quantitative Digital PCR Experiments)
checklist for this study can be found in Additional file 3.
Characterisation of panels
Homogeneity
All homogeneity analysis was performed using the
Biomark HD System for Genetic Analysis applying the
assay targeting rpoB. The variations between ten randomly
selected replicate units, each of all four types of study ma-
terials were determined in order to assess the homogen-
eity of the materials. For each unit of TB Control Plasmid
and H37Rv gDNA materials, four dPCR replicates were
performed. gDNA was extracted from each unit of BCG/
ASM and Total MTB Control whole microbe materials
using the CTAB/NaCl method described above. Each
BCG/ASM gDNA extract was diluted 1:10 in nuclease free
water (Ambion) containing sonicated human gDNA
(25 ng/μL) (Cambio) prior to analysis of 2 μL template by
Biomark HD dPCR (n = 4). Each Total MTB Control
gDNA extract was analysed without dilution by Biomark
HD dPCR (n = 4) using 3 μL template.
Stability testing
Short term stability testing (dry ice, 4 °C and 40 °C for 7
and 14 days) was performed to simulate the effect of
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transport. Details of the protocols can be found in
Additional file 1: method 3.
Reproducibility of dPCR
The reproducibility of a candidate dPCR-based reference
method for quantification of M. tuberculosis was as-
sessed through an inter-laboratory study involving four
metrology institutes each performing the rpoB assay
used in defining the material homogeneity and the 16S
rRNA assay. Plasmid and gDNA materials were analysed
using three dPCR platforms: two chip-based (Biomark
(Fluidigm) and Quantstudio 3D (Thermo Fisher Scientific)
and one droplet-based (QX100, Bio-Rad). Three of the
four laboratories also performed gDNA extraction from
the BCG/ASM material and analysed extracts using the
Biomark HD and QX100 platforms. Protocols for gDNA
extraction and dPCR were provided as per Additional
file 2; the protocol for the Quantstudio 3D method
can be found in Additional file 1: method 2.
End user analysis by clinical laboratories
To assess the role of the rigorously characterised proto-
type reference materials the BCG/ASM and Total MTB
Control materials were used to evaluate the quantitative
performance of eight different end user laboratories
(Additional file 1: Tables S4 and S5).
qPCR
Three laboratories received three units of the BCG/ASM
and Total MTB Control materials for analysis using
in-house developed gDNA extraction and qPCR pro-
tocols (Additional file 1: Table S4). One laboratory
performed both qPCR and Cepheid Xpert MTB/RIF
analysis. Laboratory identifiers were removed and re-
placed with greek numerals for the purpose of the
qPCR comparison.
Xpert MTB/RIF
Six laboratories received three units of the BCG/ASM
and Total MTB Control materials for analysis using the
Xpert MTB/RIF assay (Cepheid) (respective details in
Additional file 1: Table S5). Prior to processing, the
Total MTB Control material was re-suspended in
1.0 mL of molecular biology grade water (Ambion) and
mixed until completely reconstituted. Following thawing,
molecular biology grade water (0.6 mL) was added to
the BCG/ASM material to achieve a final volume of
1.0 mL for all test materials. Laboratories were in-
structed to process the test materials as per the manu-
facturer’s instructions for an expectorated sputum
sample using the Xpert MTB/RIF test. Laboratory iden-
tifiers were removed and replaced with numbers for the
purpose of the Xpert MTB/RIF comparison.
Data analysis
Data from the characterisation of 10 units of each study
material in terms of homogeneity was analysed in R
version 3.0.1 in order to determine the single laboratory-
assigned values. A mixed effect model was fitted with
sample unit as a random effect and the mean as the
single fixed effect. The model was fitted for concentra-
tion, for which the residuals were sufficiently normally
distributed. The means, standard errors of the means
and homogeneity uncertainties (between unit standard
deviations) were calculated.
Data from the dPCR inter-laboratory study were used
to calculate concentration values and measurement un-
certainties for the TB Control Plasmid, H37Rv gDNA
and BCG/ASM based on the approach of the assignment
of indicative copy number concentration values by dPCR
used by JRC-IRMM for reference material ERM-AD442k
[34]. Mean values for each dataset combining laboratory
and dPCR platform (for example, Laboratory 1/Biomark)
were calculated from all replicates. Copy number con-
centration values for the materials were calculated from
the mean and standard error of the six (TB Control
Plasmid, H37Rv) or five (BCG/ASM) mean values of the
respective laboratory platforms. The expanded uncer-
tainty was calculated by applying a coverage factor (k) to
the standard error at the 95 % confidence level based on
the number of degrees of freedom associated with the
number of laboratory/platform datasets (k = 2.57 for
plasmid and H37Rv gDNA, and k = 2.78 for BCG/ASM).
For the end user clinical analysis differences in mea-
surements of BCG/ASM and Total MTB Control results
were assessed by subtracting the average Cq of the
BCG/ASM from the Total MTB Control and the delta
Cq (ΔCq) was determined. For the Xpert MTB/RIF the
average Cq from the five probes was taken for each
analysis. Fold differences were calculated using the
following equation:
Fold difference ¼ 2ΔCq
Results and discusssion
Quantification of materials
In the initial stage of this study we assessed dPCR as a
method to quantify specific DNA sequences in different
prototype reference materials and assess their stability
and homogeneity to support proficiency testing of clin-
ical molecular analysis of M. tuberculosis. Three types of
materials were prepared consisting of different levels of
complexity: (i) linearised ‘TB Control Plasmid’ DNA
containing the full length rpoB and 16S rRNA genes;
(ii) purified gDNA from M. tuberculosis laboratory refer-
ence strain H37Rv and (iii) two preparations of whole
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mycobacteria in synthetic sputum: BCG/ASM material
and Total MTB Control.
Certified reference materials of defined homogeneity
have been made available for molecular testing of hu-
man cytomegalovirus [35] and BCR-ABL [36]. However,
this has to our knowledge not been done with the
intention to support molecular testing of bacteria. Estab-
lishing reference material homogeneity and stability is a
prerequisite to determine measurement precision within
and between laboratories, which is ultimately necessary
for robust quantification. This is in recognition of the
fact that different units of a batch of reference materials
can, and often do, contain different amounts of the com-
ponent being measured. These factors can, if necessary,
be mathematically considered for separating different
sources of measurement result variability.
In this study 10 randomly selected units of each ma-
terial were used to characterise the material homogen-
eity (Fig. 1) and stability (Additional file 1: Figure S1).
For the TB Control Plasmid material, no significant
difference in DNA concentration between units was ob-
served. Therefore, no allowance for homogeneity was in-
cluded in the value assignment of this material (Table 1).
For the H37Rv gDNA, BCG/ASM and Total MTB
Control Materials a contribution for homogeneity was
included in describing the respective uncertainties
(Table 1) due to differences between units (Fig. 1).
Expanded uncertainties were calculated by applying a
coverage factor (k) based on 9° of freedom for H37Rv
gDNA, BCG/ASM and Total MTB Control materials
(k = 2.26) and 30° of freedom for the Plasmid DNA ma-
terial (k = 2.04) as the between unit variability was larger
than residual technical (dPCR) variability for the H37Rv
gDNA, BCG/ASM and Total MTB Control materials,
while for the TB Control Plasmid the between unit vari-
ability was negligible.
Although we can detect quantitative differences be-
tween units by performing this assessment, we were able
to demonstrate that these differences are small and the
assessment provides the basis on which the preparation
of these materials can be improved.
The process of analysing the whole cell TB materials
also enabled us to assess dPCR in terms of accuracy, as
already performed for extracted DNA [24]. When com-
pared to CFU counting, dPCR provided a very similar
result demonstrating that both methods can deliver
equivalent results (Fig. 1c). This suggested that, when
coupled with an efficient extraction method, dPCR can
offer a complementary method to CFU counting which
is faster and, as it measures DNA, is potentially more
suitable for characterising reference materials for mo-
lecular diagnostic tests like the Xpert MTB/RIF.
Assessment of the reproducibility of the dPCR method
While dPCR may be able to provide equivalent results to
CFU counting in a single laboratory, for maximum im-
pact this must be the case with a satisfactory reproduci-
bility across multiple laboratories, ideally with different
instruments. In the next stage of the study the two DNA
materials and the BCG/ASM whole mycobacterial
* **
ba
dc
Fig. 1 Homogeneity assessment of ten randomly selected tubes of (a) TB Control Plasmid (b) H37Rv gDNA, (c) BCG/ASM and (d) Total MTB control.
* solid line depicts mean value and 95 % CI measured using colony forming units. ** solid line depicts value and range provided by the product sheet
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material were used to evaluate the reproducibility of the
dPCR method by comparing the results from three or
four different laboratories using two or three different
dPCR instruments (Fig. 2). ANOVA analysis demon-
strated a difference between laboratories when the TB
Control Plasmid was measured (p = <0.001). As this is
the least complex template investigated with the highest
intra-laboratory precision, this result suggested effects
from differences in instrument and/or laboratory setups
(Fig. 2a). Larger variations were observed for within-
and between- laboratory results for the H37Rv gDNA
(Fig. 2b) compared to TB Control Plasmid. This may be
attributable to the more complex secondary structure of
gDNA and its impact on dPCR amplification [37, 38].
However, the fact that differences in the results for plas-
mid and gDNA were not instrument specific suggests
that this is likely to be due to laboratory setups rather
than the choice of instruments. Furthermore, even with
the most complex whole cell material, the measured dif-
ferences were less than two fold (Fig. 2c).
Concentration values and measurement uncertainties
using the mean values for each combination of
Table 1 Description of test materials
Material LGC-assigned
value
Inter laboratory study
assigned value
Value Expanded measurement
uncertaintya
Value Expanded measurement
uncertaintya
Plasmid(copies/μL) 1.374 × 105 2.3 × 103 1.30 × 105 1.5 × 104
H37Rv gDNA(copies/µL) 6.83 × 104 3.4 × 103 4.8 × 104 9.0 × 103
BCG/ASM(copies/unit) 1.52 × 107 1.3 × 106 1.24 × 107 2.4 × 106
Total MTB control(copies/
unit)
3.47 × 103 6.6 × 102 N/A N/A
aMeasurement uncertainty rounded outwards to 2 s.f. Concentration values given to the same integer as measurement uncertainties
ba
c
Fig. 2 Assessment of the reproducibility of dPCR measuring (a) TB Control Plasmid and (b) H37Rv gDNA with four laboratories and three different
dPCR instruments or (c) BCG/ASM three laboratories and two different dPCR instruments
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laboratory and platform were also calculated for the TB
Control Plasmid, H37Rv gDNA and BCG/ASM mate-
rials (Table 1). The mean values calculated from the
inter-laboratory study were within 30 % of those initially
calculated by the coordinating laboratory (TB Control
Plasmid, 95 %; H37Rv gDNA, 70 % and BCG/ASM,
82 %). The measurement uncertainties estimated for the
inter-laboratory dPCR comparison study were larger
compared to those from the homogeneity study per-
formed at a single laboratory (expressed relative to the
concentration value): TB Control Plasmid, 12 % vs.
1.7 %; H37Rv gDNA, 19 % vs. 5.0 % and BCG/ASM,
19 % vs. 8.5 %. This reflects the additional sources of
measurement error such as dPCR platform and differ-
ences in execution of detection and extraction protocols
which are taken into account with inter-laboratory
comparisons.
These findings demonstrate that while there are differ-
ences between laboratory, as seen in Fig. 2, these are
small (being less than two fold). As the interlaboratory
reproducibility was predicted to be greater than this we
therefore concluded that the reproducibility of the dPCR
method was satisfactory for the remainder of this study.
These findings complement the precision and potential
trueness already described elsewhere [24, 39]. As with
the homogeneity data, these results provide a key refer-
ence point on which we can build on to better under-
stand sources of bias when measuring M. tuberculosis
using molecular methods. This can be used to further
improve reproducibility, which can in turn improve the
performance of quantitative molecular measurements
associated with TB diagnostic and prognostic monitor-
ing. In the short term, this could be achieved by using
dPCR as a reference method to quantify pathogens in
reference materials. These could in turn support more
routine application of other molecular methods, like
qPCR, when measuring M. tuberculosis and other
pathogens. Ultimately the findings presented here
make a case for dPCR to be explored and developed
as a quantitative molecular diagnostic test for diseases
like TB.
Assessment of clinical laboratories using quantitative
molecular methods
In the final part of the study we assessed how the com-
prehensively characterised BCG/ASM and Total MTB
Control whole mycobacteria prototype reference mate-
rials could be used to compare routine molecular diag-
nostic laboratories performance using either qPCR or
Xpert RIF/MTB. As both methods also provide a
quantitative output we wanted to use these materials to
explore the measurement reproducibility of the clinically
applied molecular methods independent of clinical/
biological factors.
The comparison of results showed that all laboratories
were able to determine that the BCG/ASM and Total
MTB Control materials were relatively high and low, re-
spectively, in M. tuberculosis abundance independent of
the chosen method (Additional file 1: Figure S2). When
using the Xpert MTB/RIF there was a discrepancy be-
tween the levels of bacteria reported (Additional file 1:
Figure S2). This was comparable to the findings from an
earlier study [40] with quantification cycle (Cq [41] also
known as Ct) standard deviations being less than two
cycles (Additional file 1: Figure S2c).
A problem when performing qPCR, either using an a
laboratory developed method or using the Xpert MTB/
RIF, is that the output Cq is a value that should not be
directly compared between different methods (qPCR
protocols and Xpert MTB/RIF). This is because Cq can be
influenced by a range of factors including threshold set-
ting, probe choice and instrument. It is likely that the Cq
value are more comparable between different GeneXpert
instruments than with qPCR instruments. However, as
this parameter is also influenced by amplification curve
performance and fluorescence background, a direct com-
parison of values should be approached with caution.
What can be directly compared when using qPCR are
the differences between Cq values (or ΔCq) from the
same assays measured by the same instrument [41].
Using the results from the clinical testing laboratories,
we conducted a comparison between results on the
BCG/ASM and Total MTB Control materials which
when measured using dPCR differ by a factor of ~1000.
To compare this by Xpert MTB/RIF, we used previous
work by Blakemore et al. [42] and later by van Zyl-Smit
[18] who suggested that the PCR efficiency of the Xpert
MTB/RIF approximates 100 %. Consequently a difference
of 2 Cq corresponds to a fourfold change. Of note is that
this approach must be used with caution as efficiency will
define the accuracy of the fold change estimation [43]. In
this case such a comparison demonstrated that many of
the clinical laboratories underestimated the difference be-
tween the two materials (Fig. 3). Any reduction in PCR ef-
ficiency would have further reduced the measured fold
difference all of which underestimate the difference deter-
mined by dPCR (i.e. Fig. 3 presents the best case scenario).
Variation in qPCR efficiency could explain why the vari-
ability is large for many of the results, which supports the
need to determine efficiency for precise quantification
when using qPCR.
The results presented in Fig. 3 clearly demonstrate that
the magnitude of the measured fold difference between
materials can change significantly between methods. This
is perhaps not surprising for the qPCR methods as they
use a variety of extraction and PCR methods and do not
have access to common reference materials to harmonise
their findings. Where molecular quantification has been
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established in the field of clinical virology, large differences
are experienced as the norm when performing qPCR
without access to reference materials [44].
It is noteworthy, considering how much work has
been performed assessing the Xpert MTB/RIF for quan-
tification [15–17, 19, 45], that based on these findings
speculation that such an approach used clinically to
quantify the pathogen load in a patient may be prema-
ture. At first glance the observed bias leading to reduced
fold difference estimates could be explained by the fact
that the BCG/ASM concentration is at the upper work-
ing range of the Xpert RIF/MTB, however the distribu-
tion of MTB detection level results of the BCG/ASM
suggests that this was not the cause (Additional file 1:
Figure S2a). Neither Cepheid nor the WHO recommend
the Xpert MTB/RIF for quantification and we support
this view.
While the nature of qPCR means quantification is pos-
sible, our findings suggest accuracy and reproducibility
need to be assessed and improved before this method
can be used to provide the clinical feasibility of
molecular quantification of M. tuberculosis during the
management of TB. Reference materials, such as those
described here and by others [6], are necessary to assist
in assessing laboratory proficiency in routine testing.
However, we demonstrate they also provide a mechan-
ism by which the reproducibility of molecular methods
can be evaluated during the translational stage of
method development. Furthermore, dPCR offers a
method with sufficient accuracy to quantify specific
DNA sequences in reference materials for calibration
and assessment of the performance of clinical laborator-
ies conducting molecular analysis to assist in the treat-
ment of TB.
Conclusion
Quantification is increasingly proposed as a tool to as-
sist in the management of patients with bacterial infec-
tions such as TB. However, molecular methods that
have not been validated for quantification, such as the
Xpert RIF/MTB, should be used with caution for this
purpose. The findings of this study clearly demonstrate
how rigorously characterised reference materials can
be used to evaluate within and between laboratory per-
formance. Furthermore dPCR offers a sufficiently ac-
curate method by which these materials can be
characterised. What we did not assess in this study was
the impact of factors such as different laboratory
workers, reagent lot and storage, and it is possible that
controlling these factors could improve the findings.
Reference materials would be crucial to such an effort
as they can be used to define and reduce analytical
variation and improve method performance to ultim-
ately determine if quantification of a given pathogen in
a clinical context is possible. The high accuracy of
dPCR also makes this approach potentially a more ro-
bust pathogen quantification technique for clinical
purposes in future patient management.
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Fig. 3 Fold difference between BCG/ASM and Total MTB control when measured using dPCR and compared to eight clinical testing laboratories
applying qPCR or Xpert MTB/RIF
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